找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Data Monitoring Committees (DMCs); Past, Present, and F Nand Kishore Rawat,David Kerr Book 2023 The Editor(s) (if applicable) and The Autho

[復(fù)制鏈接]
查看: 47042|回復(fù): 60
樓主
發(fā)表于 2025-3-21 18:30:22 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Data Monitoring Committees (DMCs)
副標(biāo)題Past, Present, and F
編輯Nand Kishore Rawat,David Kerr
視頻videohttp://file.papertrans.cn/263/262982/262982.mp4
概述Provides thorough instructions on the steps needed to form and implement a data monitoring committee.Includes practical and hands-on information on DMC implementation.Discusses smaller more flexible s
圖書封面Titlebook: Data Monitoring Committees (DMCs); Past, Present, and F Nand Kishore Rawat,David Kerr Book 2023 The Editor(s) (if applicable) and The Autho
描述.Thisbook provides an overview of Data Monitoring Committees(DMC) - what was donein the past, what is currently being done, and thoughts on improvementsfor the future. Previous works focused primarily on largecardiovascular studies (where DMCs originated more than 30 years ago)but updated references are needed that discuss smaller, more flexiblestudies in areas such as oncology. The authors have attended ~800 DMCmeetings from ~200 distinct studies across all areas of clinical studies(oncology, rheumatology, rare diseases, cardiology, immunology, etc.)This wide range of expertise will be used, as well as the expertise thatcomes from working with virtually every large?biotechnology and pharmaceutical company?and CROfor DMC work. The reader of the book will know when DMCs are needed orhelpful, how to form the DMC, how to work with external CROs and withsponsor teams and the DMC to create needed DMC outputs, how the DMCmeetings are conducted, and - especially for DMC members - what areconsiderations within the Closed Session to review safety/efficacyoutputs to assess risk/benefit to make appropriate recommendations thatprotect the patient safety and trial integrity..Thisis a practical
出版日期Book 2023
關(guān)鍵詞Clinical Trials drug approval; Clinical trials vaccine approval; FDA drug approval; unbiased review of
版次1
doihttps://doi.org/10.1007/978-3-031-28760-2
isbn_softcover978-3-031-28762-6
isbn_ebook978-3-031-28760-2
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

書目名稱Data Monitoring Committees (DMCs)影響因子(影響力)




書目名稱Data Monitoring Committees (DMCs)影響因子(影響力)學(xué)科排名




書目名稱Data Monitoring Committees (DMCs)網(wǎng)絡(luò)公開度




書目名稱Data Monitoring Committees (DMCs)網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Data Monitoring Committees (DMCs)被引頻次




書目名稱Data Monitoring Committees (DMCs)被引頻次學(xué)科排名




書目名稱Data Monitoring Committees (DMCs)年度引用




書目名稱Data Monitoring Committees (DMCs)年度引用學(xué)科排名




書目名稱Data Monitoring Committees (DMCs)讀者反饋




書目名稱Data Monitoring Committees (DMCs)讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:57:36 | 只看該作者
Physiogenic Hearing Impairment in Adultsta, and then making recommendations. These recommendations are made to help ensure study integrity and to protect the patients – ultimately up to recommending stopping the study to protect patient safety against undue risk, or due to established statistical futility or statistical benefit.
板凳
發(fā)表于 2025-3-22 04:26:08 | 只看該作者
地板
發(fā)表于 2025-3-22 06:32:37 | 只看該作者
5#
發(fā)表于 2025-3-22 11:38:30 | 只看該作者
https://doi.org/10.1007/978-3-031-79986-0ta is captured and categorized. Detailed list of adverse outputs of most use to the DMC is given, with numerous examples of figures. Proposals for useful summarizations (including figures) from deaths, laboratory data, vital signs data, and other data sources are also provided.
6#
發(fā)表于 2025-3-22 13:36:46 | 只看該作者
https://doi.org/10.1007/978-3-031-79986-0ssessment of risk-benefit to provide more suitable DMC recommendations. The hazards of repeated assessment of efficacy data are noted, as are the hazards of overinterpreting early trends or lack of early trends. The principles of interpreting p-values are provided.
7#
發(fā)表于 2025-3-22 18:04:05 | 只看該作者
https://doi.org/10.1007/978-3-031-79281-6t, especially for studies with more than two treatments or more than one primary treatment phase. Suggestions are provided on the look-and-feel of the DMC package sent to the DMC so that it is both comprehensive, but also comprehensible.
8#
發(fā)表于 2025-3-22 21:15:57 | 只看該作者
9#
發(fā)表于 2025-3-23 02:22:24 | 只看該作者
10#
發(fā)表于 2025-3-23 06:38:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-28 23:39
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
浠水县| 延寿县| 蒲城县| 吉林市| 彭泽县| 仲巴县| 武功县| 老河口市| 六盘水市| 句容市| 胶州市| 大冶市| 庆元县| 屏东县| 萨嘎县| 闸北区| 肇庆市| 灵丘县| 桓台县| 会泽县| 营口市| 乐至县| 卢湾区| 东台市| 淮阳县| 武清区| 绥中县| 漳浦县| 胶南市| 宜城市| 甘泉县| 横山县| 翁源县| 阿瓦提县| 馆陶县| 湘潭市| 九龙县| 靖安县| 池州市| 潞城市| 昌江|